The trial will enrol increased-risk, chemotherapy-ineligible elderly LA-HNSCC patients who are not eligible to receive platinum-based chemotherapy. Credit: KGH / commons.wikimedia.org.

Nanobiotix and LianBio have randomised the first subject in Asia in the global Phase III NANORAY-312 clinical trial of NBTXR3 to treat elderly individuals with locally advanced head and neck squamous cell carcinoma (LA-HNSCC).

The registrational, two-arm, randomised, investigator’s choice trial will evaluate the safety and efficacy of radiotherapy-activated NBTXR3 with or without cetuximab, compared to radiotherapy with or without cetuximab.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The trial will enrol increased-risk elderly LA-HNSCC patients who are not eligible to receive platinum-based chemotherapy.

Trial subjects who have received a radiotherapy of the investigator’s choice alone, or radiotherapy plus cetuximab will be categorised into a 1:1 ratio to receive NBTXR3.

The company anticipates enrolling 500 subjects into the trial across the globe, with nearly 100 participants planned to be enrolled in licenced territories of LianBio taking part in the trial.

See Also:

A new oncology product, NBTXR3 comprises functionalised hafnium oxide nanoparticles administered through a single intratumoral injection and activated using radiotherapy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In Greater China, Singapore, Thailand, and South Korea, LianBio has the exclusive rights for NBTXR3 development and marketing.

The latest trial is based on data from the Phase I Study 102 trial which assessed the safety and initial efficacy signs of radiotherapy-activated NBTXR3 in high-risk elderly patients with LA-HNSCC who are ineligible for chemotherapy and not tolerant to cetuximab.

LianBio CEO Yizhe Wang said: “We believe NBTXR3 has demonstrated the potential to improve treatment outcomes in multiple solid tumour indications, including in Study 102, the Nanobiotix Phase I trial evaluating the product candidate for the treatment of elderly patients with locally advanced head and neck squamous cell carcinoma.

“We look forward to working with our clinical partners at sites across Greater China and South Korea to evaluate NBTXR3 in this difficult-to-treat patient population.”